Tamoxifen activity against Plasmodium in vitro and in mice
Open Access
- 27 November 2019
- journal article
- research article
- Published by Springer Nature in Malaria Journal
- Vol. 18 (1) , 1-7
Abstract
Background: Tamoxifen is an oestrogen receptor modulator that is widely used for the treatment of early stage breast cancer and reduction of recurrences. Tamoxifen is also used as a powerful research tool for controlling gene expression in the context of the Cre/loxP site-specific recombination system in conditional mutant mice. Methods: To determine whether the administration of tamoxifen affects Plasmodium growth and/or disease outcome in malaria, in vitro studies assessing the effect of tamoxifen and its active metabolite 4-hydroxytamoxifen on Plasmodium falciparum blood stages were performed. Tamoxifen effects were also evaluated in vivo treating C57/B6 mice infected with Plasmodium berghei (ANKA strain), which is the standard animal model for the study of cerebral malaria. Results: Tamoxifen and its active metabolite, 4-hydroxytamoxifen, show activity in vitro against P. falciparum (16.7 to 5.8 µM IC50, respectively). This activity was also confirmed in tamoxifen-treated mice infected with P. berghei, which show lower levels of parasitaemia and do not develop signs of cerebral malaria, compared to control mice. Mice treated with tamoxifen for 1 week and left untreated for an additional week before infection showed similar parasitaemia levels and signs of cerebral malaria as control untreated mice. Conclusions: Tamoxifen and its active metabolite, 4-hydroxytamoxifen, have significant activity against the human parasite P. falciparum in vitro and the rodent parasite P. berghei in vivo. This activity may be useful for prevention of malaria in patients taking this drug chronically, but also represents a major problem for scientists using the conditional mutagenic Cre/LoxP system in the setting of rodent malaria. Allowing mice to clear tamoxifen before starting a Plasmodium infection allows the use the Cre/LoxP conditional mutagenic system to investigate gene function in specific tissues.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (1R01HL130630)
This publication has 23 references indexed in Scilit:
- Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection withLeishmania amazonensisJournal of Antimicrobial Chemotherapy, 2016
- Leishmania is not prone to develop resistance to tamoxifenInternational Journal for Parasitology: Drugs and Drug Resistance, 2015
- Possible artemisinin-based combination therapy-resistant malaria in Nigeria: a report of three casesRevista da Sociedade Brasileira de Medicina Tropical, 2013
- The Role of Animal Models for Research on Severe MalariaPLOS Pathogens, 2012
- The relevance of non-human primate and rodent malaria models for humansMalaria Journal, 2011
- Artemisone effective against murine cerebral malariaMalaria Journal, 2010
- Histological assessment of cellular half-life in tissues in vivoHistochemistry and Cell Biology, 2008
- Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotesJournal of Antimicrobial Chemotherapy, 2007
- The effect of mefloquine and volume-regulated anion channel inhibitors on induced transport in Plasmodium falciparum-infected human red blood cellsBlood Cells, Molecules, and Diseases, 2004
- Regulation of Cre Recombinase Activity by Mutated Estrogen Receptor Ligand-Binding DomainsBiochemical and Biophysical Research Communications, 1997